MRO Magazine

Implant Sciences Continues to Innovate – Granted Three More U.S. Patents for Trace Detection

By PRN NewsWire   

WILMINGTON, Mass., May 11, 2015 /PRNewswire/ — Implant Sciences Corporation (OTCQB:IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that the company has been granted three new patents by the U.S. Patent and Trademark Office.

The patents, captioned “Non-Radioactive Ion Source Using High Energy Electrons”, “Chemical Analysis Using Hyphenated Low and High Field Ion Mobility”, and “Selective Ionization Using High-Frequency Filtering of Reactive Ions,” expand Implant Sciences’ intellectual property protection and are expected to lead to even more effective company products.

“Implant Sciences is committed to providing the best and most innovative technology for our customers. We believe that the first of these three new patents, our newest non-rad ionization method, gives Implant Sciences a true competitive advantage in the field. This new design is durable, low-cost, and is compatible with high-volume manufacturing. We believe that the design, which also makes the unit easier to service in the field, will further simplify trace detection ownership and increase customer satisfaction,” noted Todd Silvestri, Implant Sciences’ Vice President of Technology.

“Implant Sciences’ other two new patents seek to dramatically improve some of the inherent limitations associated with the conventional ionization physics and chemistry currently deployed in ion mobility systems, primarily False Alarm Rates (FAR) and selectivity. The innovation in these two patents, namely hyphenating of Ion Mobility Spectrometry (IMS) and Differential Mobility Spectrometry (DMS), leads to an even higher system resolution, which increases the range of detectable threats for the system,” stated Dr. Bill McGann, CEO of Implant Sciences.

“Being able to select the type of reactive ions we want to generate, via the high-frequency filtering patent, adds another dimension of separation, leading to improved selectivity. Both of these patents should allow us to detect and identify a broader range of threats, including homemade explosives (HMEs), masking agents, and other new threats. We expect this will lead to important, real-life implications for our customers, where lives depend on technology such as ours to detect emerging terrorist threats,” Dr. McGann added.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The company’s team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 60 countries worldwide. The company’s ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the GSN Homeland Security Award for “Best Explosives Detection Solution” two years in a row (2013 and 2014). All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company’s website at

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the “Company”) related thereto contain or may contain certain “forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. Such statements are based on management’s current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company’s control) that could cause the Company’s actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our markets are subject to technological change and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; our ability to compete will depend on our ability to develop, acquire or license new patents and other intellectual property and operate without infringing on the proprietary rights of others; we may not obtain the patents we have applied for; the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; any patents we may obtain may be may be challenged and subsequently invalidated; we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.


Implant Sciences Corporation Company Contact: Robert Liscouski 978-752-1700 x 116

To view the original version on PR Newswire, visit:—granted-three-more-us-patents-for-trace-detection-300080945.html

Implant Sciences Corporation

Web site:


Stories continue below

Print this page